The molecular, the bad, and the ugly: Preventing bladder cancer via mTOR inhibition

David J. McConkey, Colin P. Dinney

Research output: Contribution to journalShort surveypeer-review

Abstract

This perspective on Seager et al. (beginning on p. 1008) considers an important advance in the effort to control bladder cancer. Frontline therapy for superficial transitional cell carcinoma of the bladder involves instillation of the crude immunomodulatory bacterial extract Bacillus Calmette-Guérin directly into the organ. Seager et al. now show that local administration of a chemical inhibitor of mammalian target of rapamycin strongly suppressed growth in a novel preclinical mouse model that develops carcinoma in situ, a particularly problematic form of transitional cell carcinoma of the bladder. The results not only support the clinical evaluation of mammalian target of rapamycin inhibitors in this setting, they open the door for the evaluation of additional molecular local therapies as well.

Original languageEnglish (US)
Pages (from-to)1001-1002
Number of pages2
JournalCancer Prevention Research
Volume2
Issue number12
DOIs
StatePublished - Dec 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The molecular, the bad, and the ugly: Preventing bladder cancer via mTOR inhibition'. Together they form a unique fingerprint.

Cite this